Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma

29 Aug 2021

Abstract excerpt

Background: MYC is a master regulator of multiple myeloma (MM) by orchestrating several pro-tumoral pathways, including reprograming of the miRNA transcriptome. MYC is also involved in the acquirement of resistance to anti-MM drugs, including immunomodulatory imide drugs (IMiDs). Methods: In silico analysis was performed on MM proprietary and on public MMRF-CoMMpass datasets. Western blot and chromatin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34503175
DOI: 10.3390/cancers13174365

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple MyelomaPMID 34503175Read ↗

MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug ResistanceSemantic proximity Read ↗

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read ↗

c‐FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myelomaSemantic proximity Read ↗

Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment.Semantic proximity Read ↗

ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple MyelomaSemantic proximity Read ↗

C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myelomaSemantic proximity Read ↗

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple MyelomaSemantic proximity Read ↗

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomideSemantic proximity Read ↗

Role of epigenetics-microRNA axis in drug resistance of multiple myelomaSemantic proximity Read ↗

SUMOylation inhibition enhances dexamethasone sensitivity in multiple myelomaSemantic proximity Read ↗

SUMOylation Inhibition Enhances Dexamethasone Sensitivity in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.